Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | BRD4 | O60885 | 8/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | BLM | P54132 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.53 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.53 |
| ▸ | TOP1 | P11387 | 2/20 | 0.49 |
| ▸ | TOP2A | P11388 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20293286 | 0.96 | HSD17B10 (0.53) | HSD17B10BRD4ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL3741042 | 0.91 | HSD17B10 (0.57) | HSD17B10BRD4ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL25780156 | 0.90 | HSD17B10 (0.56) | HSD17B10BRD4ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL3383472 | 0.90 | HSD17B10 (0.58) | HSD17B10BRD4ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL3378290 | 0.89 | AKT1 (0.62) | HSD17B10BRD4ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL25780858 | 0.89 | HSD17B10 (0.54) | HSD17B10BRD4ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL25780664 | 0.88 | HSD17B10 (0.56) | HSD17B10BRD4ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL25780050 | 0.88 | HSD17B10 (0.53) | HSD17B10BRD4ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL25781087 | 0.86 | HSD17B10 (0.54) | HSD17B10BRD4ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL25780286 | 0.86 | HSD17B10 (0.51) | HSD17B10BRD4ALDH1A1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108610293-B | Method for preparing dorvitinib intermediate by adopting microchannel reaction device | 南京工业大学 | 2020-08-04 | — | — | CN | claimed |
| WO-2023109902-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF IN MEDICINE | 海思科医药集团股份有限公司 | 2023-06-22 | — | — | WO | disclosed |
| CN-109721620-B | HPK1 inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20220002313-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIVERSITY HEALTH NETWORK (CA) | 2022-01-06 | — | — | US | disclosed |
| CN-113214287-A | HPK1 inhibitors and methods of use thereof | 大学健康网络 | 2021-08-06 | — | — | CN | disclosed |
| US-11059832-B2 | HPK1 inhibitors and methods of using same | UNIVERSITY HEALTH NETWORK (CA) | 2021-07-13 | — | — | US | disclosed |
| CN-107922431-B | HPK1 inhibitors and methods of use thereof | 大学健康网络 | 2021-06-04 | — | — | CN | disclosed |
| EP-3322711-B1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIV HEALTH NETWORK (CA) | 2021-03-10 | — | — | EP | disclosed |
| CN-108610293-B | Method for preparing dorvitinib intermediate by adopting microchannel reaction device | 南京工业大学 | 2020-08-04 | — | — | CN | disclosed |
| US-20200190104-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIVERSITY HEALTH NETWORK (CA) | 2020-06-18 | — | — | US | disclosed |
| US-20050209247-A1 | Lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; improved water solubility and physicochemical properties (e.g., stability, hygroscopicity, crystallinity, and compactibility); vascular endothelial growth factor receptor tyrosine kinase inhibitors | CHIRON CORPORATION | 2005-09-22 | — | — | US | disclosed |
| US-20050203101-A1 | Benzimidazole quinolinones and uses thereof | CHIRON CORPORATION | 2005-09-15 | — | — | US | disclosed |
| WO-2005082340-A2 | MODULATION OF INFLAMMATORY AND METASTATIC PROCESSES | CHIRON CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050137399-A1 | A lithium-free reaction to produce a substituted/unsubstituted 4-amino-3-benzimidazol-2-yl-quinolin-2-one compound by reacting a 2-aminobenzonitrile with a 2-alkyloxycarbonylmethyl-benzimidazole in a solvent in the presence of a sodium or potassium salt of a base; excellent yields | CHIRON CORPORATION | 2005-06-23 | — | — | US | disclosed |
| EP-1539754-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | Chiron Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005046590-A2 | METHODS FOR SYNTHESIZING QUINOLINONE COMPOUNDS | CHIRON CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005046589-A2 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | CHIRON CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005047244-A2 | INHIBITION OF FGFR3 AND TREATMENT OF MULTIPLE MYELOMA | CHIRON CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20040092535-A1 | Benzimidazole quinolinones and uses thereof | CHIRON CORPORATION | 2004-05-13 | — | — | US | disclosed |
| WO-2004018419-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | CHIRON CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059832-B2 | HPK1 inhibitors and methods of using same | PDXK, PDK3, PDK2 | HSD17B10 1233/4885BRD4 1780/4885ALDH1A1 2442/4885 |
| US-20050137399-A1 | A lithium-free reaction to produce a substituted/unsubstituted 4-amino-3-benzimidazol-2-yl-quinolin-2-one compound by reacting a 2-aminobenzonitrile with a 2-alkyloxycarbonylmethyl-benzimidazole in a solvent in the presence of a sodium or potassium salt of a base; excellent yields | KCNJ2, KCNN2, KCNN1 | HSD17B10 2141/4885BRD4 55/4885ALDH1A1 2263/4885 |
| US-20050203101-A1 | Benzimidazole quinolinones and uses thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, PBRM1 | HSD17B10 4442/4885BRD4 51/4885ALDH1A1 1196/4885 |
| US-20040092535-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | HSD17B10 755/4885BRD4 710/4885ALDH1A1 152/4885 |
| US-20220002313-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | PDXK, PDK3, PDK2 | HSD17B10 1201/4885BRD4 1938/4885ALDH1A1 2458/4885 |
| US-20200190104-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | PDXK, PDK3, PDK2 | HSD17B10 1233/4885BRD4 1780/4885ALDH1A1 2442/4885 |
| US-20050209247-A1 | Lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; improved water solubility and physicochemical properties (e.g., stability, hygroscopicity, crystallinity, and compactibility); vascular endothelial growth factor receptor tyrosine kinase inhibitors | KDR, FLT4, FLT1 | HSD17B10 2437/4885BRD4 2562/4885ALDH1A1 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.